BioCentury | Jul 21, 2014
Clinical News

Infliximab regulatory update

...to launch the drug next quarter. Celltrion plans to market it in the country with Mustafa Nevzat...
BioCentury | Jun 18, 2012
Company News

Amgen, Mustafa Nevzat Pharmaceuticals A/S deal

...Amgen completed its acquisition of more than 99% of Mustafa Nevzat in a cash deal that values...
...Mustafa. Details were not disclosed (see BioCentury, April 30). Amgen Inc. (NASDAQ:AMGN), Thousand Oaks, Calif. Mustafa Nevzat Pharmaceuticals A/S...
BioCentury | Apr 30, 2012
Finance

Turkish injection

...Inc. (NASDAQ:AMGN) has dipped into an emerging market via M&A. This time, it is buying Mustafa Nevzat...
...revenue. The cash deal values the Turkish generic injectable company at $700 million. Last year, Mustafa Nevzat...
...on dialysis. Amgen also has several products under regulatory review in Turkey. Klem likened the Mustafa Nevzat...
BioCentury | Apr 30, 2012
Company News

Amgen, Mustafa Nevzat Pharmaceuticals A/S deal

...95.6% of Mustafa Nevzat in a cash deal that values the Turkish pharma at $700 million. Mustafa Nevzat...
...on how the deal would affect its financial guidance. Amgen Inc. (NASDAQ:AMGN), Thousand Oaks, Calif. Mustafa Nevzat Pharmaceuticals A/S...
BioCentury | Apr 26, 2012
Top Story

Amgen buying Turkish pharma

...Amgen Inc. (NASDAQ:AMGN) said it will acquire 95.6% of Mustafa Nevzat Pharmaceuticals A.S. (Istanbul, Turkey) in a...
...A.S. (Istanbul, Turkey) in a cash deal that values the Turkish pharma at $700 million. Mustafa Nevzat...
Items per page:
1 - 5 of 5
BioCentury | Jul 21, 2014
Clinical News

Infliximab regulatory update

...to launch the drug next quarter. Celltrion plans to market it in the country with Mustafa Nevzat...
BioCentury | Jun 18, 2012
Company News

Amgen, Mustafa Nevzat Pharmaceuticals A/S deal

...Amgen completed its acquisition of more than 99% of Mustafa Nevzat in a cash deal that values...
...Mustafa. Details were not disclosed (see BioCentury, April 30). Amgen Inc. (NASDAQ:AMGN), Thousand Oaks, Calif. Mustafa Nevzat Pharmaceuticals A/S...
BioCentury | Apr 30, 2012
Finance

Turkish injection

...Inc. (NASDAQ:AMGN) has dipped into an emerging market via M&A. This time, it is buying Mustafa Nevzat...
...revenue. The cash deal values the Turkish generic injectable company at $700 million. Last year, Mustafa Nevzat...
...on dialysis. Amgen also has several products under regulatory review in Turkey. Klem likened the Mustafa Nevzat...
BioCentury | Apr 30, 2012
Company News

Amgen, Mustafa Nevzat Pharmaceuticals A/S deal

...95.6% of Mustafa Nevzat in a cash deal that values the Turkish pharma at $700 million. Mustafa Nevzat...
...on how the deal would affect its financial guidance. Amgen Inc. (NASDAQ:AMGN), Thousand Oaks, Calif. Mustafa Nevzat Pharmaceuticals A/S...
BioCentury | Apr 26, 2012
Top Story

Amgen buying Turkish pharma

...Amgen Inc. (NASDAQ:AMGN) said it will acquire 95.6% of Mustafa Nevzat Pharmaceuticals A.S. (Istanbul, Turkey) in a...
...A.S. (Istanbul, Turkey) in a cash deal that values the Turkish pharma at $700 million. Mustafa Nevzat...
Items per page:
1 - 5 of 5